Nuclear Repressors in Genomic Control of Healthful Obesity

健康肥胖基因组控制中的核抑制因子

基本信息

批准号：
9271966
负责人：
Grant D Barish
金额：
$ 33.93万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-05-10 至 2021-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9271966
关键词：
Ablation Address Adipocytes Adipose tissue Anatomy Animals BCL6 gene Benign Binding Body fat CCAAT-Enhancer-Binding Proteins Cells Central obesity ChIP-seq Closure by clamp Data Development Diet Disease Drug or chemical Tissue Distribution Energy Metabolism Epigenetic Process Exhibits Fatty acid glycerol esters Gene Targeting Genes Genetic Genetic Engineering Genetic Transcription Genomics Health Heart Diseases Hepatic High Fat Diet Histology Histones Hormonal Hyperplasia Hypertrophy Immune Indirect Calorimetry Inflammation Insulin Resistance Isotopes Knockout Mice Lipids Lipolysis Magnetic Resonance Imaging Measurement Measures Mediating Metabolic Metabolic Diseases Metabolism Molecular Morbidity - disease rate Mus Non-Insulin-Dependent Diabetes Mellitus Nuclear Nuclear RNA Nuclear Receptors Obesity PPAR gamma Pathology Pathway interactions Peripheral Physiological Physiology Production Regulation Regulator Genes Repression Risk Role Signal Pathway Site Skin Somatotropin Switch Genes Testing Therapeutic Tissue Banks Tissue Expansion Tissues Transcription Repressor/Corepressor Transplantation Visceral X-Ray Computed Tomography adipocyte differentiation adipokines base blood glucose regulation cardiometabolic risk disorder risk epigenomics feeding genome-wide glucose production glucose uptake improved in utero in vivo insight insulin sensitivity lipid biosynthesis lipid metabolism male novel therapeutics prevent programs public health relevance response sexual dimorphism subcutaneous transcriptome sequencing

项目摘要

DESCRIPTION (provided by applicant): It has long been recognized that central (visceral) obesity is associated with adverse metabolic health including insulin resistance, yet peripheral (subcutaneous) body fat is healthful or benign, a distinction believed to underlie the sexually dimorphic risk of cardiometabolic disease with obesity. However, the molecular determinants that control the origins and physiology of these functionally distinct depots are poorly defined. Using conditional genetic engineering, we have identified a surprising role for the B cell lymphoma 6 (BCL6) transcriptional repressor in depot-specific adipose tissue programming. We find that BCL6 co-localizes with key adipocytic transcriptional regulators PPARγ, C/EBP, and EBF1 to control a metabolic gene regulatory network through cis-regulatory sites in differentiated adipocytes. Consequently, adipocyte-specific loss of BCL6 in utero results in spontaneous and selective expansion of subcutaneous, but not visceral, adipose tissue, identifying BCL6 as a new key regulator of sexually dimorphic obesity and distribution. Herein, we propose to dissect the genomic integration of BCL6 with nuclear receptor and hormonal signaling pathways to determine its role as a key regulator of adipose tissue distribution and function, using comprehensive cell and molecular, genomic, and physiologic approaches with endpoints of insulin sensitivity by euglycemic-hyperinsulinemic clamp, adipokine production, and lipid metabolism. Given that distinct adipose tissue depots exert differential risk of insulin resistance and cardiometabolic disease, our studies of BCL6 will reveal new therapeutic pathways to reduce the morbidity of obesity including type 2 diabetes mellitus (DM2).

描述（由申请人提供）：人们早就认识到，中枢性（内脏）肥胖与包括胰岛素抵抗在内的不良代谢健康有关，但外周（皮下）身体脂肪是健康的或良性的，这一区别被认为是性别二态性风险的基础。然而，控制这些功能不同的库的起源和生理学的分子决定因素尚不清楚，利用条件基因工程，我们发现了 B 细胞淋巴瘤的令人惊讶的作用。 (BCL6) 储库特异性脂肪组织编程中的转录抑制因子，我们发现 BCL6 与关键脂肪细胞转录调节因子 PPARγ、C/EBP 和 EBF1 共定位，通过分化脂肪细胞中的顺式调节位点控制代谢基因调节网络。子宫内脂肪细胞特异性缺失 BCL6 会导致皮下脂肪组织而非内脏脂肪组织自发选择性扩张，从而识别BCL6 作为性二态性肥胖和分布的新关键调节因子本文中，我们建议利用综合细胞和方法剖析 BCL6 与核组织受体和激素信号通路的基因组整合，以确定其作为脂肪分布和功能的关键调节因子的作用。分子、基因组和生理学方法通过正常血糖-高胰岛素钳夹、脂肪因子产生和脂质代谢来确定胰岛素敏感性终点，因为不同的脂肪组织库会产生不同的风险。胰岛素抵抗和心脏代谢疾病，我们对 BCL6 的研究将揭示降低肥胖（包括 2 型糖尿病 (DM2)）发病率的新治疗途径。